Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden

  • M Wagenius
  • Åke Borg
  • L Johansson
  • Aleksander Giwercman
  • Ola Bratt
Publishing year: 2006
Language: English
Pages: 23-25
Publication/Series: Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00
Volume: 40
Issue: 1
Document type: Journal article
Publisher: Taylor & Francis

Abstract english

Objective. CHEK2* 1100delC is a frame-shifting germ-line mutation which abolishes the function of cell-cycle-checkpoint kinase 2 (chk2) and hence impairs the cells' response to DNA damage. This variant occurs in approximate to 1% of the general Western population but has been reported to be more common among patients with breast and prostate cancer. The aim of this study was to investigate the significance of CHEK2* 1100delC as a possible high-risk gene for hereditary prostate cancer in the population of southern Sweden. Material and methods. We screened for the CHEK2* 1100delC variant in 419 men diagnosed with prostate cancer in southern Sweden, 145 of whom were sporadic cases that were divided into two subgroups depending on whether they were diagnosed before ( n = 64) or after ( n = 81) the age of 55 years. A further 126 men were classified as familial prostate cancer cases and 148 as hereditary prostate cancer cases. The control group consisted of 305 military conscripts aged approximate to 18 years ( range 18 - 21 years). Results. The CHEK2* 1100delC variant was found in 1.2% of the cases ( sporadic: 0.7%; familial: 1.6%; hereditary: 1.4%) and in 1.0% of the controls. Conclusion. The CHEK2 1100delC mutation is not a clinically important high-risk gene for hereditary prostate cancer susceptibility in the population of southern Sweden.


  • Urology and Nephrology
  • Cancer and Oncology
  • cell-cycle-checkpoint kinase 2
  • genetics
  • germ-line mutation
  • risk factors
  • prostatic neoplasms
  • CHEK2


  • Reproductive medicine, Malmö
  • Urology
  • ISSN: 0036-5599
Åke Borg
Åke Borg
E-mail: ake [dot] borg [at] med [dot] lu [dot] se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2


Project manager

Familial Breast Cancer



Oncology and Pathology, MV

MV 404 C21C2